Your Shopping Cart Is Empty
| Report Code: A10292 | Feb 2021 | Pages: 109 | ||
| Tables: 33 | Charts: 35 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the U.s. Cardiac Resynchronization Therapy Market
Request Now !The U.S. cardiac resynchronization therapy market size was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027.
COVID-19 outbreak had considerable impact on the U.S. cardiac resynchronization therapy market. A 73% reduction in the CRT pacemaker implantation and decrease of more than 25% in the cardiac resynchronization therapy defibrillator implantation was observed during the COVID?19 pandemic period among few states in the U.S.
Cardiac resynchronization therapy (CRT) is a treatment to assist heart beat with the right rhythm. It uses a pacemaker to restore the normal timing pattern of the heartbeat. CRT is a procedure to implant a device in the chest to make patient's heart's chambers squeeze (contract) efficiently. Cardiac resynchronization therapy is traditionally a treatment for patients who experience heart failure and then develop an arrhythmia. Cardiac resynchronization therapy finds applications in the intraventricular dyssynchrony, interventricular dyssynchrony, and atrioventricular dyssynchrony.
Factors that drive the growth of the CRT market include surge in elderly population, rise in prevalence of cardiovascular diseases (CVDs), increase in technological advances in the CRT pacemakers and CRT defibrillators, and surge in healthcare expenditure in the U.S. For instance, as per the statistics published by Centers for Disease Control and Prevention (CDC), about 6.2 million adults in the U.S. have heart failure. One patient dies every 36 seconds in the U.S. from cardiovascular disease. Heart disease is the leading cause of death for men, women, and individuals of most racial and ethnic groups in the country. Furthermore, around 655,000 Americans die from heart disease each year, which is one in every four deaths.
On the contrary, high cost of CRT therapy as well as the presence of stringent regulations for CRT devices in the U.S. are anticipated to restrain the U.S. cardiac resynchronization therapy market growth during the forecast period.
The U.S. cardiac resynchronization therapy market is categorized into type, application, and end user. On the basis of type, the market is segmented into CRT pacemaker and CRT defibrillator. CRT pacemaker was introduced first within the healthcare industry in 1994. Pacemaker is a small electronic device, implanted below the collarbone and are connected to the heart through wires (leads) to the right chambers of the heart. The CRT defibrillator segment led the market in 2019, and is expected to continue this trend throughout the forecast period attributed to an increase in adoption of CRT defibrillators over CRT pacemakers as well as the launch of technologically advanced CRT defibrillators.
On the basis of application, the U.S. cardiac resynchronization therapy market is classified into intraventricular dyssynchrony, interventricular dyssynchrony, and atrioventricular dyssynchrony. Interventricular dyssynchrony refers to the discordance between the times of right ventricular (RV) and left ventricular (LV) contraction, or delay in segmental wall motion. Intraventricular dyssynchrony is the principal factor responsible for contractile dysfunction, the one most affected by and most predictive of response to resynchronization therapy. The intraventricular dyssynchrony segment spearheaded the market in 2019 in terms of revenue attributed to comparatively higher incidence of intraventricular dyssynchrony among patients with heart failure and left bundle branch block.
On the basis of end user, the U.S. cardiac resynchronization therapy market is classified into hospitals, ambulatory surgical centers, and specialized cardiac treatment centers. Being the primary point for diagnosis and treatment of cardiovascular disease coupled with rise in adoption of cardiac resynchronization therapy devices in the hospital settings, the hospital segment is anticipated to witness supremacy throughout the review period.
The cardiac resynchronization therapy market is highly competitive in nature, as major players in this vertical are concentrating on growth strategies such as product launches, mergers and acquisitions (M&As), partnerships and collaborations to gain competitive advantage. For instance, in January 2020, Medtronic plc received CE Mark (Europe) for its Cobalt and Crome portfolio of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy-defibrillators (CRT-D). ICDs monitor heart rhythms and deliver therapy to correct heart rates that are too fast and can lead to sudden cardiac arrest. Cobalt and Crome heart devices deliver the opportunity of a personalized approach to defibrillator therapy. In addition, in July 2020, the U.S. Food and Drug Administration (USFDA) has approved Abbott's next-generation Gallant implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices in the U.S. These devices provide efficient battery longevity and MRI compatibility. In addition, the new devices offer Bluetooth technology and a new patient smartphone app for improved remote monitoring, allowing for increased patient/physician engagement and streamlined communications.
The key players operating in the U.S. cardiac resynchronization therapy market include Medtronic plc, Abbott Laboratories, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Lepu Medical Technology (Beijing) Co., Ltd., LivaNova PLC, MEDICO S.p.A., MicroPort Scientific Corporation, OSCOR Inc., and Osypka Medical GmbH.
Key Benefits For Stakeholders
U.S. Cardiac Resynchronization Therapy Market Report Highlights
| Aspects | Details |
|---|---|
| By Type |
|
| By Application |
|
| By End User |
|
| Key Market Players | MEDTRONIC PLC, MICROPORT SCIENTIFIC CORPORATION, OSYPKA MEDICAL GmbH, MEDICO S.P.A., LIVANOVA PLC, LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD., BIOTRONIK SE & CO. KG, OSCOR INC., BOSTON SCIENTIFIC CORPORATION, ABBOTT LABORATORIES |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Surge in geriatric population along with rise in prevalence of cardiovascular diseases
3.4.1.2.Technological advancements in the CRT devices
3.4.1.3.Surge in healthcare infrastructure in the U.S.
3.4.2.Restraints
3.4.2.1.High cost of CRT devices
3.4.2.2.Product recalls in the U.S.
3.4.2.3.Shortage of healthcare professionals in U.S.
3.4.3.Opportunity
3.4.3.1.Emerging opportunities in the low economic U.S. states
3.4.4.Impact analysis
3.5.Impact analysis of COVID-19 on the cardiac resynchronization therapy market
CHAPTER 4:U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast, by type
4.2.CRT pacemaker
4.2.1.Market size and forecast
4.3.CRT defibrillator
4.3.1.Market size and forecast
CHAPTER 5:U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast, by application
5.2.Intraventricular dyssynchrony
5.2.1.Market size and forecast
5.3.Interventricular dyssynchrony
5.3.1.Market size and forecast
5.4.Atrioventricular dyssynchrony
5.4.1.Market size and forecast
CHAPTER 6:U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast , by end user
6.2.Hospitals
6.2.1.Market size and forecast
6.3.Ambulatory surgical centers
6.3.1.Market size and forecast
6.4.Specialized cardiac treatment centers
6.4.1.Market size and forecast
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.BOSTON SCIENTIFIC CORPORATION
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments
7.3.BIOTRONIK SE & CO. KG
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Key strategic moves and developments
7.4.LIVANOVA PLC
7.4.1.Company overview
7.4.2.Operating business segments
7.4.3.Product portfolio
7.4.4.Business performance
7.5.LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.6.MEDTRONIC PLC
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.MICROPORT SCIENTIFIC CORPORATION
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments
7.8.MEDICO S.P.A.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.9.OSCOR INC.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.10.OSYPKA MEDICAL GmbH
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
LIST OF TABLES
TABLE 01.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 02.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 03.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 04.ABBOTT: COMPANY SNAPSHOT
TABLE 05.ABBOTT: OERATING SEGMENT
TABLE 06.ABBOTT: PRODUCT PORTFOLIO
TABLE 07.BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 08.BOSTON SCIENTIFIC: OPERATING SEGMENTS
TABLE 09.BOSTON SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 10.BIOTRONIK: COMPANY SNAPSHOT
TABLE 11.BIOTRONIK: OPERATING SEGMENTS
TABLE 12.BIOTRONIK: PRODUCT PORTFOLIO
TABLE 13.LIVANOVA: COMPANY SNAPSHOT
TABLE 14.LIVANOVA: OPERATING SEGMENT:
TABLE 15.LIVANOVA: PRODUCT PORTFOLIO
TABLE 16.LEPU MEDICAL: COMPANY SNAPSHOT
TABLE 17.LEPU MEDICAL: OPERATING SEGMENTS
TABLE 18.LEPU MEDICAL: PRODUCT PORTFOLIO
TABLE 19.MEDTRONIC: COMPANY SNAPSHOT
TABLE 20.MEDTRONIC: OPERATING SEGMENTS
TABLE 21.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 22.MICROPORT: COMPANY SNAPSHOT
TABLE 23.MICROPORT: OPERATING SEGMENTS
TABLE 24.MICROPORT: PRODUCT PORTFOLIO
TABLE 25.MEDICO: COMPANY SNAPSHOT
TABLE 26.MEDICO: OPERATING SEGMENTS
TABLE 27.MEDICO: PRODUCT PORTFOLIO
TABLE 28.OSCOR: COMPANY SNAPSHOT
TABLE 29.OSCOR: OERATING SEGMENT
TABLE 30.OSCOR: PRODUCT PORTFOLIO
TABLE 31.OSYPKA MEDICAL: COMPANY SNAPSHOT
TABLE 32.OSYPKA MEDICAL: OPERATING SEGMENTS
TABLE 33.OSYPKA MEDICAL: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020
FIGURE 06.LOW BARGAINING POWER OF SUPPLIERS
FIGURE 07.HIGH BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.IMPACT ANALYSIS
FIGURE 12.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR CRT PACEMAKER, 2019-2027 ($MILLION)
FIGURE 13.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR CRT DEFIBRILLATOR, 2019-2027 ($MILLION)
FIGURE 14.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR INTRAVENTRICULAR DYSSYNCHRONY, 2019-2027 ($MILLION)
FIGURE 15.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR INTERVENTRICULAR DYSSYNCHRONY, 2019-2027 ($MILLION)
FIGURE 16.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR ATRIOVENTRICULAR DYSSYNCHRONY, 2019-2027 ($MILLION)
FIGURE 17.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR HOSPITALS, 2019-2027 ($MILLION)
FIGURE 18.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR AMBULATORY SURGICAL CENTERS, 2019-2027 ($MILLION)
FIGURE 19.U.S. CARDIAC RESYNCHRONIZATION THERAPY MARKET FOR SPECIALIZED CARDIAC TREATMENT CENTERS, 2019-2027 ($MILLION)
FIGURE 20.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 21.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 22.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 23.BOSTON SCIENTIFIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.BOSTON SCIENTIFIC: NET SALES, BY SEGMENT, 2019 (%)
FIGURE 25.BOSTON SCIENTIFIC: NET SALES, BY REGION, 2019 (%)
FIGURE 26.LIVANOVA: NET SALES, 2017-2019 ($MILLION)
FIGURE 27.LIVANOVA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.LIVANOVA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 29.MEDTRONIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.MEDTRONIC: REVENUE SHARE BY CARDIAC RHYTHM & HEART FAILURE SEGMENT, 2020 (%)
FIGURE 32.MEDTRONIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33.MICROPORT: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.MICROPORT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.MICROPORT: REVENUE SHARE, BY REGION, 2019 (%)
The U.S. cardiac resynchronization therapy market is expected to showcase profitable growth in the future. The market growth is characterized by factors such as growth in aging population, rise in sedentary lifestyle, surge in prevalence of cardiovascular diseases (CVDs), increase in technological developments in the CRT pacemakers and CRT defibrillators, the presence of advanced healthcare infrastructure, and surge in healthcare expenditure in the U.S.
As per the analysis in the report, the CRT defibrillator segment will be the highest contributor in the market throughout the forecast period pertaining to an increase in adoption of CRT defibrillators over CRT pacemakers as well as the launch of technologically advanced CRT defibrillators.
On the contrary, high cost of CRT therapy as well as the presence of stringent regulations for CRT devices in the U.S. are anticipated to restrict the market growth during the forecast period. The initial cost of cardiac resynchronization therapy pacemaker (CRT-P) is $16,218.44 and of cardiac resynchronization therapy defibrillator (CRT-D) is $36,263.73. Thus, this high cost of CRT therapy is anticipated to limit the market growth during the forecast period.
A. A surge in elderly population coupled with rise in prevalence of cardiovascular diseases (CVDs) will drive the market over the near future according to the KOLs.
A. The market has drawn the interest of the healthcare industry, owing to increase in technological advances in the CRT pacemakers and CRT defibrillators, and surge in healthcare expenditure in the U.S.
A. By type, the CRT defibrillator segment holds the maximum market share.
A. Cardiac resynchronization therapy is traditionally a treatment for patients who experience symptoms of heart failure and arrhythmia.
A. Cardiac resynchronization therapy is a treatment to help the heart beat with the right rhythm.
A. The total value of the U.S. cardiac resynchronization therapy market was $965.6 million in 2019.
A. The forecast period in the report is from 2020-2027.
A. The market value of cardiac resynchronization therapy market in 2027 is expected to reach $983.3 million.
A. The base year calculated in the report is 2019.
Start reading instantly.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report